Reacción a "EMA revises earlier decision and decides to approve lecanemab for Alzheimer's disease"

This is in line with what the UK’s MHRA decision, that, in a subset of patients with early Alzheimer’s disease, the benefits of treatment exceed the risks. This is not to say that lecanemab is clinically or cost-effective. 

I anticipate that the bodies that determine cost-effectiveness of new drugs within individual jurisdictions will struggle to approve lecanemab for use in their public health systems. The treatment is expensive and benefits are marginal.